David Chi Cheong Wan,Yan Wang,Wai Kit Law,Jian Shu Hu,Tsz Ming Ip
申请号：
US14920892
公开号：
US09968616B2
申请日:
2015.10.23
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
